Advertisement
Review
The challenge of providing access to high-priced patented medicines is a global problem affecting all countries. A decade and a half ago the use of flexibilities contained in the World Trade Organization Agree...
Journal of Pharmaceutical Policy and Practice 2017 10:19
Published on: 28 June 2017
Research
Barriers to expanding access to medicines include weak pharmaceutical sector governance, lack of transparency and accountability, inadequate attention to social services on the political agenda, and financing ...
Journal of Pharmaceutical Policy and Practice 2017 10:18
Published on: 2 June 2017
Research
Many middle-income countries are scaling up health insurance schemes to provide financial protection and access to affordable medicines to poor and uninsured populations. Although there is a wealth of evidence...
Journal of Pharmaceutical Policy and Practice 2017 10:17
Published on: 16 May 2017
Research
Medicines use related challenges such as inadequate adherence, high levels of antimicrobial resistance and preventable adverse drug reactions have underscored the need to incorporate pharmaceutical services to...
Journal of Pharmaceutical Policy and Practice 2017 10:16
Published on: 8 May 2017
Research
The Affordable Medicines Facility for malaria (AMFm) Program was a subsidy aimed at artemisinin-based combination therapies (ACTs) in order to increase availability, affordability, and market share of ACTs in ...
Journal of Pharmaceutical Policy and Practice 2017 10:15
Published on: 28 April 2017
Research
The purpose of this study is to explore medication-related perceptions of adult patients with type 2 diabetes attending treatment in public hospitals of urban centers in central Ethiopia.
Journal of Pharmaceutical Policy and Practice 2017 10:14
Published on: 8 April 2017
Research
The inappropriate use of antimicrobials is a problem worldwide. To target future interventions, a thorough understanding of the reasons behind this current behaviour is needed. Within the EU, the culture of an...
Journal of Pharmaceutical Policy and Practice 2017 10:13
Published on: 4 April 2017
Policy analysis
This article aims to highlight the positions of the Food and Drug Administration and the European Medicines Agency regarding use and marketing of hydroxyethyl starch (HES) products, and how these have changed ...
Journal of Pharmaceutical Policy and Practice 2017 10:12
Published on: 21 March 2017
Policy Analysis
It is essential to allocate available resources equitably in order to ensure accessibility and affordability of essential medicines, especially in less fortunate nations with limited health funding. Currently,...
Journal of Pharmaceutical Policy and Practice 2017 10:11
Published on: 27 February 2017
Commentary
When patients are told that standard medical treatment options have been exhausted, their treating physicians may start looking for promising new drugs that are not yet approved, and still under investigation....
Journal of Pharmaceutical Policy and Practice 2017 10:10
Published on: 21 February 2017
Research
Lack of regulatory capacity limits the conduct of ethical and rigorous trials of herbal medicines in developing countries. Sharing ethical and regulatory experiences of successful herbal trials may accelerate ...
Journal of Pharmaceutical Policy and Practice 2017 10:9
Published on: 20 February 2017
Research
Asthma as a chronic health condition can be controlled when in addition to clinical care, adequate education and support is provided to enhance self-management. Like many other chronic health conditions improv...
Journal of Pharmaceutical Policy and Practice 2017 10:8
Published on: 7 February 2017
Research
Private-sector retail drug outlets are often the first point of contact for common health ailments, including tuberculosis (TB). Systematic reviews on public-private mix (PPM) interventions for TB did not perf...
Journal of Pharmaceutical Policy and Practice 2017 10:6
Published on: 18 January 2017
Research
To assess the effect of policies supporting local medicine production to improve access to medicines.
Journal of Pharmaceutical Policy and Practice 2017 10:7
Published on: 16 January 2017
Research
The WHO Model List of Essential Medicines for Children (EMLc) covers medicines for globally high-burden diseases. Regulatory approval in high-income countries ensures evidence and dosage form but usually focus...
Journal of Pharmaceutical Policy and Practice 2017 10:4
Published on: 6 January 2017
Research
The Medicines Transparency Alliance (MeTA) is an initiative that brings together all stakeholders in the medicines market to create a multi-stakeholder dialogue and improve access, availability and affordabili...
Journal of Pharmaceutical Policy and Practice 2017 10:5
Published on: 6 January 2017
Research
This study aims at identifying predictors of the treatment decision of German physicians with regard to a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a ritonavir-boosted protease inhibitor (PI/r)...
Journal of Pharmaceutical Policy and Practice 2016 9:39
Published on: 30 December 2016
Research
There is substantial evidence of poor dispensing practices with inadequate packaging and labelling of medicines, and limited advice on their usage in low and middle-income countries (LMICs). We examined the la...
Journal of Pharmaceutical Policy and Practice 2016 9:38
Published on: 25 November 2016
Review
It has been proven that the interaction between pharmaceutical representatives and physicians can directly influence the latter’s prescribing behaviour. This meta-synthesis aims to explore the available studie...
Journal of Pharmaceutical Policy and Practice 2016 9:37
Published on: 17 November 2016
Commentary
The globalization of pharmaceutical production has not been accompanied by a strengthening and harmonization of the regulatory systems worldwide. Thus, the global market is characterized today by a situation o...
Journal of Pharmaceutical Policy and Practice 2016 9:36
Published on: 10 November 2016
Short Report
High oral bioavailability of antimicrobial agents can result in the replacement of intravenous (IV) therapy with oral therapy when a patient meets defined clinical criteria. However, few studies have evaluated...
Journal of Pharmaceutical Policy and Practice 2016 9:35
Published on: 28 October 2016
Research
The increasing threat of antimicrobial resistance combined with the paucity of new classes of antibiotics represents a serious public health challenge. New treatment technologies could, in theory, have a signi...
Journal of Pharmaceutical Policy and Practice 2016 9:34
Published on: 26 October 2016
Editorial
The development of new therapies has a rich history, evolves quickly with societal trends, and will have an exciting future. The last century has seen an exponential increase in complex interactions between me...
Journal of Pharmaceutical Policy and Practice 2016 9:33
Published on: 25 October 2016
Research
Annual immunization is the most effective way to prevent influenza and its associated complications. However, optimal immunization rates are not being met in Nova Scotia, Canada. Additional providers, such as ...
Journal of Pharmaceutical Policy and Practice 2016 9:32
Published on: 19 October 2016
Review
The emergence and spread of antibiotic resistant pathogens poses a big challenge to policy-makers, who need to oversee the transformation of health systems that evolved to provide easy access to these drugs in...
Journal of Pharmaceutical Policy and Practice 2016 9:31
Published on: 7 October 2016
